A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.
about
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesGenetic susceptibility to lung cancer--light at the end of the tunnel?Assessment, origin, and implementation of breath volatile cancer markers.Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parametersQuantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complexMALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives.Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression modelA novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants.State-of-the-art MS technology applications in lung disease.Epidemiology of lung cancer prognosis: quantity and quality of life.Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery.Proteomics as a guiding tool for more effective personalized therapy.Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.The morphological and molecular diagnosis of lung cancer.Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.Seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitis.Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.In-depth proteomic analysis of nonsmall cell lung cancer to discover molecular targets and candidate biomarkers.The state of molecular biomarkers for the early detection of lung cancer.Urine proteomics to detect biomarkers for chronic allograft dysfunction.Mass spectrometry-based proteomic profiling of lung cancer.Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinomaDiscovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphomaA new frontier in personalized cancer therapy: mapping molecular changes.Proteomic biomarkers in lung cancer.Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer.Comparative proteomic analysis of non-small-cell lung cancer and normal controls using serum label-free quantitative shotgun technology.Predicting the future for people with lung cancer.Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer.[Research Progress of Biomakers Proteomics-based in Lung Cancer].[Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin
P2860
Q26768158-1B9D5BA7-653D-4A6A-9734-54C3C219062DQ26852320-28EEE87E-8C62-4A90-9CEB-E0E401F96349Q27692565-6CE4E4B5-6020-4817-8AEA-49E30474EE01Q28396602-F4E4E798-479B-4E5E-B10D-B0981AE2F686Q28536191-F7E467B0-0CCE-4867-A320-B79CF6AA0A34Q30470146-11629636-9D1D-41D7-A347-D27644169042Q30500051-CAE8BDE7-C144-46A0-BF01-E08B8F4190C5Q33761618-254E4C2E-C4EA-47C2-9AB4-E0D6F9D050ECQ34089332-6353E623-CCFD-4C57-A3C8-793E06B97EF9Q34135295-A59A6B7E-150C-409B-8564-959DA26E16D3Q34350615-971358F4-0AFB-42F0-8C2D-783AF04DDDDBQ34480451-AD8A9EB6-7036-4D49-B949-5B8B234538CDQ34623884-88EF9423-6C20-46E3-9EFE-2850A71ECCE8Q35186535-C3B12013-2E52-40E8-B588-723459D66984Q35771994-4DB91C82-DE48-4AA1-868F-BB78C773047BQ35990884-5C85EC71-E56F-47AE-A843-70BE7A102F7AQ36030339-4C104EAF-B67E-4705-9D78-E1CAB23171E1Q36288148-32B35343-83A8-4695-826D-9455F50DDF1CQ36386730-DEDA93B7-3227-480E-BE3B-AD0D78FD30DFQ37044593-F84ABE6C-2623-49EC-88D8-01577FB1407AQ37086665-C222818B-C8A7-41F6-9948-42779D27E349Q37171914-38306912-D349-4475-8FEE-F49080652EC6Q37301923-EF8682FC-1F6E-4E53-9C6C-969E9E02B7F8Q37595680-899F274B-F673-4E00-A599-F0ABB321C741Q37898108-3CE9D9B8-9911-45E5-BC53-E882AE5606D6Q38100750-B130EBF6-1E73-4121-A2A4-777F404FACA2Q38172914-69E993A5-A2DF-4037-8C8A-B38F69AB3E6BQ42654558-0F81E028-66F9-47C9-BC7F-D82AC0BC4849Q42878612-DBFD0D0F-1DC9-4858-9DE3-AA4210781FDCQ51557016-604F22A9-DEBB-4841-B26F-8BA79D4BA305Q55058467-61238057-8411-49C8-B98B-E8DA2A44D455Q55464368-6690AFB7-8A95-4875-B269-A6FDD477F8F7Q55464639-56498CD1-8D52-455E-869A-B77E6D0F1923Q58799114-CC43F9F8-E9B3-47F6-864E-4936B5D86C19
P2860
A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A 25-signal proteomic signatur ...... ed non-small-cell lung cancer.
@ast
A 25-signal proteomic signatur ...... ed non-small-cell lung cancer.
@en
A 25-signal proteomic signatur ...... ed non-small-cell lung cancer.
@nl
type
label
A 25-signal proteomic signatur ...... ed non-small-cell lung cancer.
@ast
A 25-signal proteomic signatur ...... ed non-small-cell lung cancer.
@en
A 25-signal proteomic signatur ...... ed non-small-cell lung cancer.
@nl
prefLabel
A 25-signal proteomic signatur ...... ed non-small-cell lung cancer.
@ast
A 25-signal proteomic signatur ...... ed non-small-cell lung cancer.
@en
A 25-signal proteomic signatur ...... ed non-small-cell lung cancer.
@nl
P2093
P50
P356
P1476
A 25-signal proteomic signatur ...... ted non-small-cell lung cancer
@en
P2093
Kiyoshi Yanagisawa
Shuta Tomida
Yukako Shimada
P304
P356
10.1093/JNCI/DJK197
P407
P577
2007-06-01T00:00:00Z